陕西省药品生产企业和研究机构新药研发能力现状及发展策略

发布时间：2018-05-02 00:25

本文选题：陕西省 + 药品生产企业　；参考：《中国医药工业杂志》2017年01期

【摘要】：分析陕西省药品生产企业和研究机构新药研发能力、存在的问题,探讨提升新药研发能力的策略。检索数据库,收集2001~2015年陕西省药品生产企业和研究机构的新药申报数量、获批情况、现有批准文号数量。结果显示,陕西省大中型药品生产企业是研发活动的主体,创新药物的研究成果显著,新药研发趋于理性,医药领域投资并购升温,政府对创新药物的支持力度逐年增大。建议树立开放式创新理念、多渠道增加新药研发投入、促进新药技术转移、关注国家医药政策导向、发挥"一带一路"战略支点上的陕西优势。
[Abstract]:This paper analyzes the problems existing in the research and development of new drugs in Shaanxi pharmaceutical production enterprises and research institutions, and probes into the strategies to improve the ability of new drug research and development. The database was searched to collect the number of new drug applications and the number of approved numbers of drug manufacturers and research institutes in Shaanxi Province from 2001 to 2015. The results show that large and medium-sized pharmaceutical production enterprises in Shaanxi Province are the main body of R & D activities, the research results of innovative drugs are remarkable, the research and development of new drugs tend to be rational, the investment and merger and acquisition in the field of medicine are heating up, and the government's support for innovative drugs is increasing year by year. It is suggested that we should set up an open innovation idea, increase R & D investment through many channels, promote new drug technology transfer, pay close attention to the guidance of national medicine policy, and give play to Shaanxi's superiority in the strategic fulcrum of "Belt and Road".
【作者单位】：西安交通大学医学部药学院药事管理与临床药学系;西安新通药物研究有限公司;西安交通大学药品安全与政策研究中心;
【基金】：陕西省社会科学基金项目(13SC021) 西安交通大学青年拔尖人才项目
【分类号】：R95;F426.72

【参考文献】